Development of TCR Technology Platforms for Cancer Immunotherapy

• Highlight how next-generation of single chain TCR can prevent mispairing
• Share preclinical insights showing the potential of engineered stimulatory PD-L1 signalling for solid tumour applications
• Showcase the platform of targeted transduction for nonactivated T-cells

Speakers:

Shao-An Xue

Professor

University College London